You don't have to have finely honed news instincts to realize that if GlaxoSmithKline failed to disclose everything it knew about Avandia to the Food & Drug Administration, you are sure to have a big story.
So you will probably be reading a lot about the warning letter issued by FDA to GSK after inspecting the firm's post-market adverse event reporting procedures.
Many in industry may be tempted to dismiss the letter as just the latest in a series of woes for GSK and its once-blockbuster type 2 diabetes therapy, just more piling on to a bad news story that is almost exactly a year old.
That would be a mistake. The warning letter should be a must read for all biopharma companies with products on the market (and all companies who hope to be so lucky as to have products some day). The letter does indeed add to GSK's headaches, but for the rest of industry it should serve as notice that the agency is likely to do a lot more enforcement of post-marketing study reporting requirements in the months and years ahead.
Congress, remember, has just handed FDA new enforcement authority over post-marketing trials, in the form of the ability to mandate Phase IV studies--and fine sponsors who fail to live up to their commitments.
The violations FDA cited in the letter to GSK predate enactment of the FDA Amendments Act in 2007, but the agency is sending an unambiguous message: there is no excuse for failing to comply with basic reporting requirements that already existed in law.
According to FDA, the agency found that GSK failed to include updates on as many as 18 different post-marketing trials in its annual reports to the agency on Avandia. GSK notes that the missing reports were inadvertent and disclosed to the agency before the final safety labeling update on Avandia in November. FDA doesn't dispute that this is a case of mistakes rather than deliberate concealment. That, in fact is the point.
Here is the key part of the letter:
FDA's inspection revealed that your firm lacked appropriate knowledge of the studies associated with Avandia, resulting in the reporting deficiencies noted. Absent a clear explanation of the extent and cause of these deficiencies and an adequate plan to correct them, we are concerned that similar deficiencies in the postmarket reporting for your firm's other FDA-approved drugs may exist . We expect that your corrective actions will include a comprehensive evaluation of your firm's reporting of postmarketing studies for all drug products for which your firm holds an approved application.
And in case you haven't read our analysis before, executives at all levels should bear in mind that the FD&C Act is a "strict liability" statute, meaning that top executives--starting with the CEO--can be held criminally accountable for violations they knew nothing about. (Indeed, as is FDA's policy, the letter to GSK is addressed to the CEO, JP Garnier.)
At this point, GSK is saying all the right things. “We take these findings seriously, and corrective steps to make sure we file periodic reports completely and promptly have been taken or are underway,” the company says in a statement. The company notes that many of the trials were in fact disclosed to FDA anyway, just not in the annual report as the agency says they should have been. And, the company adds, many of the studies were also publicly disclosed on the government's ClinicalTrials.gov website and through GSK's own on-line trial registry.
"GSK is committed to taking the appropriate steps to address the concerns raised by the FDA." The rest of the industry would do well to do the same.